Navigation Links
IRSF announces funding of first clinical trial with disease-modifying therapy for Rett syndrome
Date:9/21/2009

(Cincinnati, OH) - Today, the International Rett Syndrome Foundation announced that it will provide $200,000 in 2009 to support a newly proposed clinical trial with a growth-factor based treatment for Rett Syndrome. The study will be carried out by a team of clinical trials specialists at the Boston Children's Hospital, led by Dr. Omar Khwaja MD, PhD and will be the first potentially disease modifying therapy ever to be tested in Rett syndrome patients. Investigators will test a drug called Increlex. This is an engineered form of the human protein Insulin-like Growth Factor-1, an FDA approved drug for children with short stature due to severe Primary IGF-1 deficiency. Preliminary evidence in animal models of Rett syndrome has recently suggested that targeting the IGF-1 signaling axis may provide a potential avenue for therapy.

"We are pleased to announce the funding of this groundbreaking new clinical study which presents a novel therapeutic strategy for the treatment of Rett syndrome" said Dr. Antony Horton Chief Scientific Officer at the International Rett Syndrome Foundation. "This study will be carried out by a collaborative network of leading clinicians and neuroscientists in some of the World's most prestigious research institutes at the cutting edge of biomedical research. Through our funding of this study we demonstrate our commitment to moving forward the most advanced treatments to prevent, treat and ultimately reverse Rett syndrome".

Dr. Omar Khwaja, principal investigator on the study commented further "Since the 2007 studies which demonstrated potential reversal of Rett syndrome in animal models, there has been a paradigm shift in our thinking about ways to treat this devastating condition. Our pilot study will utilize an existing FDA approved medication, seeking to boost growth of synapses in the brain of patients with Rett syndrome".

Increlex will be provided gratis by Tercica Inc., A Subsidiary
'/>"/>

Contact: Mary Joyce Griffin
mgriffin@rettsyndrome.org
513-870-4378
International Rett Syndrome Foundation
Source:Eurekalert

Page: 1 2

Related biology news :

1. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
2. LaserCard Corporation Announces Expansion of Middle East Project
3. BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution
4. Balzan Foundation announces 2007 winners
5. The American Society of Plant Biologists announces 2007 awards
6. ASPB announces Summer Undergraduate Research Fellowship 2007 recipients
7. NIST announces 56 new awards for innovative technology research and development
8. Titanium Group Announces Contract With Haitong Securities
9. Measurement Specialties, Inc. Announces Impact of German Business Tax Reform 2008 Resulting in Lower Combined German Tax Rate - Impacts 2Q08 Reported Financial Results
10. FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change
11. HGS announces positive Phase 2 LymphoStat-B at ACR meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2015)... Conn. , Feb. 23, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... has filed provisional patent 62114357 for DISTRIBUTED ... this patent, NXT-ID introduces a new groundbreaking payment method. ... the payment account may only be accessed if both ...
(Date:2/13/2015)... TAIPEI , Feb. 13, 2015 ... service company that aims to transform cancer genomic ... announced that the company has raised US$ 8 million ... Based in Taipei, Taiwan ... tests, ACTDrug™, ACTOnco™. With the aim to implement ...
(Date:2/11/2015)... , February 11, 2015 ... research report "Access Control Market by Product (Cards and ... Residential, Military and Defense, Government, Industrial, Healthcare, Education) and ... published by MarketsandMarkets, the Access Control Market ... 2020, growing at a CAGR of 10.6% ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3ACT Genomics Raises $8 Million in its First Private Funding Round 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
... NEWS SERVICE, Weekly Press Package, November 14, 2007 ... Service Weekly press package (PressPac) with reports selected from ... With more than 160,000 members, ACS is ... journal, or the American Chemical Society, as the source ...
... nanoparticles that, when pulsed with an electromagnetic field, release ... Nov. 15 online issue of Advanced Materials, could lead ... In earlier work the team, led by Sangeeta ... of Health Sciences & Technology (HST) and in MIT,s ...
... 16, 2007) -- Honeybees somehow manage to efficiently collect a ... after all, the queen bee is too busy ... best nectar can be found on any given morning. According ... swarm intelligence of these amazingly organized bees can also be ...
Cached Biology News:American Chemical Society's Weekly PressPac -- Nov. 14, 2007 2American Chemical Society's Weekly PressPac -- Nov. 14, 2007 3American Chemical Society's Weekly PressPac -- Nov. 14, 2007 4American Chemical Society's Weekly PressPac -- Nov. 14, 2007 5American Chemical Society's Weekly PressPac -- Nov. 14, 2007 6American Chemical Society's Weekly PressPac -- Nov. 14, 2007 7American Chemical Society's Weekly PressPac -- Nov. 14, 2007 8American Chemical Society's Weekly PressPac -- Nov. 14, 2007 9American Chemical Society's Weekly PressPac -- Nov. 14, 2007 10MIT: Remote-control nanoparticles deliver drugs directly into tumors 2Bee strategy helps servers run more sweetly 2Bee strategy helps servers run more sweetly 3
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
(Date:2/27/2015)... Cytokinetics, Incorporated (Nasdaq: CYTK) announced today ... patients and health care advocates in the United States ... Rare Disease Day is dedicated to elevating public ... special challenges faced by patients with rare diseases and ... to stand alongside patients and caregivers representing the rare ...
(Date:2/27/2015)... BOSTON , Feb. 27, 2015   PureTech ... identifying, inventing and commercializing disruptive products and technologies in ... Christopher Viehbacher , former CEO and Member of the ... Directors.  "It,s has been a pleasure ... very excited that we will be working together more ...
(Date:2/26/2015)... , Feb. 26, 2015 On behalf of ... affiliated companies, Wilentz, Goldman & Spitzer, P.A. ... lawsuit against Genewiz Inc. in excess of $10 million. ... GenScript,s trade secrets, and that it improperly hired one ... order denying motions for judgment notwithstanding the verdict, a ...
Breaking Biology Technology:Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... YORK, Sept. 17 iiBIG,s New Directions ... Profitable Deal Strategies,conference is scheduled for October ... Nevada. The sessions will cover developments in ... liposome,drug delivery, tumor targeting and other novel ...
... assistive technologies, BETHESDA, Md., Sept. 17 ... a subsidiary of,Hanger Orthopedic Group, earned the esteemed ... the WalkAide(R) System. In the spirit of the,15th ... da Vinci Awards,founded by the NMSS, honor outstanding ...
... Hernia repair is one of the most commonly performed surgical procedures ... ... Ga., Sept. 17 CryoLife, Inc. (NYSE:,CRY), a biomaterials, medical device ... agreement allowing Proxy,Biomedical Limited to include CryoLife,s BioGlue(R) Surgical Adhesive into,a ...
Cached Biology Technology:Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIG's Plenary Panel in Vegas 2Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIG's Plenary Panel in Vegas 3Innovative Neurotronics, a Subsidiary of Hanger Orthopedic Group, Earns the 2007 da Vinci Award for the WalkAide System 2Innovative Neurotronics, a Subsidiary of Hanger Orthopedic Group, Earns the 2007 da Vinci Award for the WalkAide System 3CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes 2CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes 3
...
Water Distilled (Gibco™) is membrane filtered and endotoxin screened....
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
The Hybrid Hunter Yeast Two-Hybrid System uses the activation of reporter genes to indicate positive protein-protein interactions. Two reporters are used an auxotrophic marker and lacZ....
Biology Products: